文献速递主动脉疾病

开窗分支腔内修复完整复杂主动脉瘤的成本效果分析的范围综述

A scoping review of the rationale and evidence for cost-effectiveness analysis of fenestrated-branched endovascular repair for intact complex aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2020-05-27

本范围综述检索了PubMed、Ovid Embase和Scopus数据库,纳入截至2019年12月31日的英文文献,评估开窗分支腔内修复(F/B-EVAR)治疗完整复杂主动脉瘤的成本效果。未发现随机临床试验或针对不适合开放手术患者的卫生经济学评价;基于观察性研究的模型显示增量成本效果比为96,954美元/质量调整生命年,而近期美国数据库分析显示开放手术总住院费用更高且并发症更多。

要点

  • F/B-EVAR治疗完整复杂主动脉瘤的成本效果证据有限且结论不一致。
  • 支架移植物费用是F/B-EVAR初始住院费用较高的主要驱动因素。
  • 近期美国数据显示开放手术总住院费用和并发症率高于F/B-EVAR。

核心结论

  • 关于F/B-EVAR治疗完整复杂主动脉瘤的成本效果分析文献稀缺且结论不明确。
  • 基于有限非随机证据,支架移植物是F/B-EVAR费用的主要驱动因素,其相对于开放手术的成本效果可能因医疗环境和患者选择而异。

研究设计与样本

  • 范围综述,检索PubMed、Ovid Embase和Scopus数据库,纳入从建库至2019年12月31日的英文文献。
  • 未发现评估F/B-EVAR与开放手术治疗完整复杂主动脉瘤成本效果的随机临床试验。
  • 未发现针对不适合开放手术患者使用F/B-EVAR的卫生经济学评价研究。

主要发现

  • 基于2006至2014年发表的七项观察性中心或注册研究的Markov模型分析显示,F/B-EVAR相比开放手术的增量成本效果比为96,954美元/质量调整生命年。
  • 法国WINDOW注册研究(2010-2012)中,F/B-EVAR临床结果与开放手术相似但费用更高,因此在经济上被支配。
  • 在2年时,近肾/肾周动脉瘤和膈下胸腹主动脉瘤的F/B-EVAR费用更高,而膈上胸腹主动脉瘤费用相似。
  • 费用差异主要源于初始住院费用相差24,278美元(占2年费用差异的95%),由支架移植物费用导致。
  • 近期美国数据库分析(879例胸腹主动脉瘤修复,45%为开放手术)显示,开放手术未调整总住院费用中位数显著高于F/B-EVAR(44,355美元 vs 36,612美元;P = .004)。

关键数值与推荐

  • Markov模型分析报告F/B-EVAR相比开放手术的增量成本效果比为96,954美元/质量调整生命年。
  • 法国WINDOW注册研究中F/B-EVAR因费用更高且临床结果相似而被认为经济上被支配。
  • 美国数据库分析中开放手术总住院费用中位数44,355美元,F/B-EVAR为36,612美元(P = .004)。

临床怎么用

  • 临床决策需结合医疗环境、患者选择及支架移植物费用综合评估F/B-EVAR的经济性。
  • 对于不适合开放手术的复杂主动脉瘤患者,F/B-EVAR提供微创选择,但需关注其成本效果证据的局限性。

局限性

  • 纳入的研究均为观察性设计,存在选择偏倚,可能影响结局。
  • 各中心复杂腔内主动脉修复经验差异较大。
  • 缺乏随机临床试验和针对不适合开放手术患者的卫生经济学评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cost-effectiveness analysis of new interventions is increasingly required by policymakers. For intact complex aortic aneurysms (CAAs), fenestrated-branched endovascular aneurysm repair (F/B-EVAR) offers a minimally invasive alternative option for patients who are physically ineligible for open surgical repair (OSR). Thus, F/B-EVAR is increasingly used, but whether it represents a cost-effective treatment option remains unknown. METHODS: A scoping review of the literature was conducted from the PubMed, Ovid Embase, and Scopus databases. They were searched to identify relevant English-language articles published from inception to December 31, 2019. All costs in the identified literature were transformed to U.S. dollar values by the following exchange rate: 1 GBP = 1.3 USD; 1 EUR = 1.1 USD. RESULTS: At this literature search, no randomized clinical trials assessing cost-effectiveness of F/B-EVAR vs OSR for intact CAAs were found. Also, no health economic evaluation studies were found regarding use of F/B-EVAR in patients unfit for OSR. A Markov model analysis based on seven observational center- or registry-based studies published from 2006 to 2014 found that the incremental cost-effectiveness ratio for F/B-EVAR vs OSR was $96,954/quality-adjusted life-year. In the multicenter French Medical and Economical Evaluation of Fenestrated and Branched Stent-grafts to Treat Complex Aortic Aneurysms (WINDOW) registry (2010-2012), F/B-EVAR had a higher cost than OSR for a similar clinical outcome and was therefore economically dominated. At 2 years, costs were higher with F/B-EVAR for juxtarenal/pararenal aneurysms and infradiaphragmatic thoracoabdominal aneurysms but similar for supradiaphragmatic thoracoabdominal aneurysms. The higher costs were related to a $24,278 cost difference of the initial admission (95% of the difference at 2 years) due to stent graft costs. Both these studies, however, included a highly varying center experience with complex endovascular aortic repair, and their retrospective design is subject to selection bias for chosen treatment, which could affect the studied outcome. In contrast, in a more recent U.S. database analysis (879 thoracoabdominal aortic aneurysm repairs, 45% OSRs), the unadjusted total hospitalization cost of OSR was significantly higher compared with F/B-EVAR (median, $44,355 vs $36,612; P = .004). In-hospital mortality as well as major complications were two to three times higher after OSR, indicating that endovascular repair might be the economically dominant strategy. CONCLUSIONS: The literature regarding cost-effectiveness analysis of F/B-EVAR for intact CAAs is scarce and ambiguous. Based on the limited nonrandomized available evidence, stent grafts are the main driver for F/B-EVAR expenses, whereas cost-effectiveness in relation to OSR may vary by health care setting and selection of patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. D'Oria M, Wanhainen A, DeMartino RR, et al. A scoping review of the rationale and evidence for cost-effectiveness analysis of fenestrated-branched endovascular repair for intact complex aortic aneurysms. J Vasc Surg. 2020. PMID: 32473347. doi:10.1016/j.jvs.2020.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。